Biocon Limited

NSEI:BIOCON Rapport sur les actions

Capitalisation boursière : ₹697.3b

Biocon Croissance future

Future contrôle des critères 4/6

Biocon devrait augmenter ses bénéfices et son chiffre d'affaires de 47.6% et de 13.1% par an respectivement. Le BPA devrait croître de de 44.5% par an. Le rendement des capitaux propres devrait être 5.7% dans 3 ans.

Informations clés

47.6%

Taux de croissance des bénéfices

44.49%

Taux de croissance du BPA

Biotechs croissance des bénéfices35.4%
Taux de croissance des recettes13.1%
Rendement futur des capitaux propres5.68%
Couverture par les analystes

Good

Dernière mise à jour21 May 2026

Mises à jour récentes de la croissance future

Article d’analyse • Aug 10

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...
Article d’analyse • Jun 19

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...

Recent updates

Article d’analyse • May 21

Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture

The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
Mise à jour du récit • May 03

BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside

Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.
Mise à jour du récit • Apr 19

BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry

Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.
Mise à jour du récit • Apr 05

BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside

Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.
Mise à jour du récit • Mar 21

BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals

Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.
Mise à jour du récit • Mar 07

BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals

Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.
Mise à jour du récit • Feb 21

BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns

Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.
Mise à jour du récit • Feb 07

BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns

Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).
Mise à jour du récit • Jan 23

BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside

Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).
Mise à jour du récit • Jan 09

BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns

Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).
Mise à jour du récit • Dec 26

BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns

Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.
Article d’analyse • Dec 25

Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...
Mise à jour du récit • Dec 12

BIOCON: Future Share Dilution Risk Will Likely Pressure Returns

Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).
Article d’analyse • Dec 07

Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel

You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...
Mise à jour du récit • Nov 27

BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks

Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.
Article d’analyse • Nov 19

Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...
Mise à jour du récit • Nov 13

BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance

Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.
Mise à jour du récit • Oct 05

Biosimilars Demand Will Unlock Global Market Opportunities

Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.
Article d’analyse • Sep 22

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...
Article d’analyse • Aug 10

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...
Article d’analyse • Aug 04

Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now

Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...
Article d’analyse • Jun 19

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...
Article d’analyse • Jun 18

Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50

The board of Biocon Limited ( NSE:BIOCON ) has announced that it will pay a dividend on the 5th of September, with...
User avatar
Nouveau récit • Dec 12

Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability

Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.

Prévisions de croissance des bénéfices et des revenus

NSEI:BIOCON - Estimations futures des analystes et données financières antérieures (INR Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
3/31/2029249,13321,93924,82747,1416
3/31/2028228,62819,94527,42741,52218
3/31/2027200,53413,69222,77538,09618
3/31/2026169,2703,85682319,940N/A
12/31/2025168,2746,042N/AN/AN/A
9/30/2025164,7584,85517,97341,592N/A
6/30/2025157,7073,850N/AN/AN/A
3/31/2025152,61710,13317,17940,612N/A
12/31/2024147,6188,043N/AN/AN/A
9/30/2024148,94114,39221,04540,368N/A
6/30/2024147,66015,808N/AN/AN/A
3/31/2024147,55710,22510,22329,539N/A
12/31/2023146,12512,002N/AN/AN/A
9/30/2023135,9994,984-6,24111,717N/A
6/30/2023124,5734,197N/AN/AN/A
3/31/2023111,7424,6271,26218,525N/A
12/31/202298,0913,881N/AN/AN/A
9/30/202290,4226,170-6,83611,543N/A
6/30/202285,6297,084N/AN/AN/A
3/31/202281,8406,484-7,48211,766N/A
12/31/202175,8006,727N/AN/AN/A
9/30/202172,6326,542-6,36612,763N/A
6/30/202171,7266,852N/AN/AN/A
3/31/202171,4317,405-5,86611,597N/A
12/31/202068,9135,996N/AN/AN/A
9/30/202067,5716,362-6,57610,484N/A
6/30/202065,7966,870N/AN/AN/A
3/31/202063,0057,771-5,53412,831N/A
12/31/201963,1508,385N/AN/AN/A
9/30/201961,0778,529N/A14,573N/A
6/30/201958,5659,919N/AN/AN/A
3/31/201955,1449,053N/A11,546N/A
12/31/201851,5518,220N/AN/AN/A
9/30/201846,7226,967N/AN/AN/A
6/30/201843,1984,108N/AN/AN/A
3/31/201841,2343,724N/A6,621N/A
12/31/201738,7923,695N/AN/AN/A
9/30/201738,5894,489N/AN/AN/A
6/30/201738,3615,268N/AN/AN/A
3/31/201738,9116,121N/A6,400N/A
12/31/201640,48711,633N/AN/AN/A
9/30/201638,11010,961N/AN/AN/A
6/30/201636,5399,388N/AN/AN/A
3/31/201633,4745,504N/A3,706N/A
12/31/201532,9977,367N/AN/AN/A
9/30/201532,3257,247N/AN/AN/A
6/30/201531,5285,207N/AN/AN/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de BIOCON ( 47.6% par an) est supérieure au taux d'épargne ( 6.9% ).

Bénéfices vs marché: Les bénéfices de BIOCON ( 47.6% par an) devraient croître plus rapidement que le marché Indian ( 16.4% par an).

Croissance élevée des bénéfices: Les bénéfices de BIOCON devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de BIOCON ( 13.1% par an) devrait croître plus rapidement que le marché Indian ( 10.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de BIOCON ( 13.1% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de BIOCON devrait être faible dans 3 ans ( 5.7 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/21 01:00
Cours de l'action en fin de journée2026/05/21 00:00
Les revenus2026/03/31
Revenus annuels2026/03/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Biocon Limited est couverte par 39 analystes. 18 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Rohit Bhat360 ONE Capital Market Private Limited
Meeta ShettyAsian Markets Securities Private Limited
Harith AhamedAvendus Spark